Surgical intervention plays an important role in the diagnosis, staging, and treatment of malignant pleural mesothelioma (MPM) and can be applied with curative or palliative intent. The overall aim of surgery should be, as in any oncologic surgery, the macroscopic complete resection (MCR) of the tumor. Most importantly, the majority of patients with the diagnosis of MPM should be appropriately staged and initially evaluated in a multidisciplinary setting, including medical oncology, radiation oncology, and surgery after histologic diagnosis. Surgical staging, including determination of the histologic subtype and lymph node status, as well as clinical staging with positron-emission tomographycomputer tomography scan and determination of cardiopulmonary reserve are crucial. Herein, we summarize the role of surgical resection, specifically macroscopic complete resection, performed as extrapleural pneumonectomy or extended pleurectomy/decortication in multimodality treatment settings and advocate for optimal patient selection for one or the other procedure. In addition, the roles of surgery in diagnosis of MPM and in palliative care are discussed.
Introduction
Surgical intervention plays an important role in the diagnosis, staging, and treatment of malignant pleural mesothelioma (MPM) and can applied with curative or palliative intent. Most published guidelines include surgery as a major component of therapy for mesothelioma (e.g., the European Society for Medical Oncology and the National Comprehensive Cancer Network), as depicted in the European Society for Medical Oncology clinical practice guidelines for the following indications 1, 2 : (1) to obtain sufficient diagnostic samples of tumor tissue and to stage the patient; (2) for palliative management of pleural effusions when chest tube drainage is not sufficient; (3) as a part of a multimodality treatment, preferable as part of a study; and (4) for definitive resection to perform macroscopic complete resection (MCR) by means of (extended) pleurectomy/decortication ([e]P/D) or extrapleural pneumonectomy (EPP).
The American Society of Clinical Oncology is recommending the use of curative-intent surgery with maximal cytoreduction in its 2018 guideline on the management of patients with MPM. 3 In fact, it has been shown in an analysis of the present Surveillance, Epidemiology, and End Results database that surgery alone is a superior form of therapy in terms of overall survival when compared to no surgery or radiotherapy alone (Fig. 1 ). 4 Indeed, most physicians in the majority of experienced mesothelioma treatment centers would agree that patients benefit from combinations of surgery with either neoadjuvant and/or adjuvant treatment that includes chemotherapy. The overall aim of surgery should be, as in any oncologic surgery, the MCR of the tumor. Maximal cytoreduction has been successfully used in other cancers that expand into a cavity such as ovarian cancer or pseudomyxoma peritonei. 5 MCR has been defined in a consensus report in 2011 as removal of all grossly visible and palpable tumor. 6 However, some groups define MCR as resection with as complete as less than 1 cm of tumor left behind. 7 Using a completeness of cytoreduction score as used for the resection of peritoneal tumors could be useful for addressing this problem in the future. 5 MCR can be achieved by either EPP or (e)P/D. Rice et al. 6 have recommended the following terminology to define surgical therapy for MPM: (1) EPP: en bloc resection of the parietal and visceral pleura with the ipsilateral lung, pericardium, and diaphragm. In cases where the pericardium and/or diaphragm are not involved by tumor, these structures may be left intact; (2) (e) P/D: parietal and visceral pleurectomy performed to remove all gross tumor with resection of the diaphragm and/or pericardium. The International Association for the Study of Lung Cancer (IASLC) Mesothelioma Domain suggests use of the term "extended" rather than "radical" in this instance as the latter implies a completeness of resection with added therapeutic benefit. There is currently insufficient evidence that resection of the pericardium and diaphragm provides either, except when it is required to accomplish MCR; (3) P/D: parietal and visceral pleurectomy performed to remove all gross tumor without diaphragm or pericardial resection, which is possible in a subset of cases; and (4) Partial pleurectomy: partial removal of parietal and/ or visceral pleura for diagnostic or palliative purposes but leaving gross tumor behind (Fig. 2) .
Most importantly, the majority of patients with the diagnosis of MPM should be initially evaluated in a multidisciplinary setting, including medical oncology, radiation oncology, and surgery after histologic diagnosis including determination of the histologic subtype and clinical staging with positron-emission tomography/ computerized tomography scan and mediastinal staging. Patients should be carefully vetted before surgery from both functional and tumor-related perspectives. Tumor factors associated with improved survival include epithelioid histology, absence of lymph node involvements, limitation to the ipsilateral chest, and low tumor burden. Patients with evidence of any extrathoracic spread should be evaluated to confirm distant disease, for example, by laparoscopy for transdiaphragmatic involvement, before surgery. Patients with confirmed preoperative sarcomatoid histology are best candidates for clinical trials giving the usual poor outcome. Frail or elderly patients, those with ongoing weight loss and/or pain should be carefully assessed because of higher risk for extrathoracic involvement and perioperative morbidity. Likewise, patients with biopsyconfirmed positive lymph nodes should be considered for clinical trial before surgery. Patients presenting with pain are more likely to be unresectable and a careful search for evidence of extrathoracic invasion by magnetic resonance imaging should be made before consideration of surgery. Patients with poor performance scores should not be encouraged to undergo surgery.
The present review aims to summarize the role of surgical MCR performed as EPP or (e)P/D in multimodality treatment settings and advocate the optimal patients' selection for one or the other procedure. In addition, the role of surgery in diagnosis of MPM and in palliative settings will be discussed.
Surgical Biopsies
Histopathologic analysis of pleural tissue is mandatory for final MPM diagnosis but can be difficult because mesothelioma is a heterogeneous cancer and the pleura is also a common site for metastatic disease, including lung cancer which occurs nearly 100 times more commonly. Three principal histologic subtypes can be differentiated according to the WHO 2004 classification 9 : the epithelioid, the sarcomatoid, and a mixture of both including at least 10% of each growth pattern -the biphasic subtype, and the desmoplastic subtype. The recommendation of the Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons strongly support a thoracoscopic tissue biopsy to obtain multiple and deep tissue biopsy specimens. 10 This may be even more important in the age of genomic medicine when multiple analyses are required. It has been shown that cytological assessment of pleural effusion may not be sensitive and specific enough when compared to a biopsy. 11 Also, fine needle biopsies are not primarily recommended because they are associated with low sensitivity (w30%). 11 A conclusive diagnosis can only be made if the material is representative in terms of biopsy location (normal and abnormal pleura and deep enough to assess fat and/or muscle tumor invasion) and sufficient quantity provides enough material to allow immunohistochemical characterization. 12 Usually a uniportal thoracoscopic approach is used in the sixth intercostal space at the site of a future incision for the larger resection so that port-site can be easily excised avoiding future local recurrences. In selected cases of MPM suspicion without additional pleural effusion, a mini-thoracotomy with direct open biopsy can be diagnostic.
Extrapleural Pneumonectomy
EPP was first attempted for curative resection of MPM by Butchart in 1976 . In his published series of 29 surgical patients, EPP was performed through a posterolateral thoracotomy and entailed extrapleural dissection to include in the final specimen the pleura, lung, ipsilateral diaphragm, and pericardium. The resection is performed through intrapericardial control and division of the hilar structures including as well an extensive lymphadenectomy. The results were compared with 17 patients who received nonsurgical treatments. In this series, prolonged survival was achieved in 3 patients; however, the perioperative mortality rate was 31%. 13 During the past 30 years, surgeons at the Brigham and Women's Hospital, Memorial Sloan Kettering Cancer Center, New York University, Toronto General Hospital, University Hospitals of Vienna and Zurich, and others worked to standardize and modernize this operation and the perioperative care to significantly decrease the morbidity and mortality of EPP while extending overall survival in the setting of multimodality therapy. [14] [15] [16] Patient selection criteria and techniques for intraoperative and postoperative management have been refined over this time. Currently, EPP is defined as the en bloc resection of the pleura, lung, diaphragm, and pericardium, excision of previous biopsy and chest tube sites, and radical mediastinal lymphadenectomy and other lymph nodes such as found in the mammary chain, along the intercostal structure and in the costodiaphragmatic region, as well as reconstruction of the diaphragm and pericardium with prosthetic patches to prevent herniation.
It was shown that EPP could be performed with acceptable morbidity and mortality (19% and 6%, respectively), while achieving MCR in the majority of patients. 17 As the number of patients in the series increased over time, the observation of extended survival in patients with epithelial histology and extrapleural node negative disease helped identify a subset of patients who would benefit from aggressive multimodality treatment. 18 In the early series, positive surgical margins did not appear to affect survival. However, subsequent analysis of 183 patients revealed that 20% of patients with negative resection margins, negative extrapleural lymph nodes, and epithelial histology experienced long-term median survival of 5 years. 19 These series established the groundwork for current practice of preoperative staging with mediastinoscopy and advanced imaging modalities, including magnetic resonance imaging and positron-emission tomography/computed tomography, to identify those patients who would benefit maximally from surgery and adjuvant therapy.
Moreover, in an analysis of 117 patients surviving at least 3 years after EPP, clinicopathologic features including age, female gender, epithelial tumor histology, and normal white blood cell, hemoglobin, or platelet count were considered favorable prognostic factors. 20 This study identified that even patients with advanced stage disease could experience prolonged survival, while acknowledging the heterogeneity of adjuvant therapy as well as the retrospective nature of the analysis. The study also showed comparable perioperative morbidity compared to other series suggesting that EPP-associated complications, when successfully managed, do not limit long-term survival. 20 One of the most difficult decisions is whether to proceed to surgery or not. Laparoscopy or contralateral Adapted with permission. 30 CI, confidence interval; EPP, extrapleural pneumonectomy; OR, odds ratio.
pleuroscopy should be performed in case of suspicion of intra-abdominal or contralateral disease in staging imaging. Mediastinal staging is performed via endobronchial ultrasound or mediastinoscopy to exclude N3 disease. 11 For further decision-making, prognostic markers have been summarized to scores for an algorithm to follow by several groups.
The analysis of prognostic factors to identify patient groups benefitting from multimodality therapy led to the development of different prognostic scores, such as the Multimodality Prognostic Score developed in a patient cohort receiving induction chemotherapy followed by EPP. This and other scores were developed to facilitate the decision for surgery after induction chemotherapy or in general. 21 The Multimodality Prognostic Score score includes four variables: pre-chemotherapy tumor volume (>500 mL) measured by dedicated software, progressive disease after induction chemotherapy (according to modified Response Evaluation Criteria in Solid Tumor [RECIST] criteria), pre-chemotherapy CRP (>30 mg/ mL), and nonepithelioid histologic subtype. It has been assessed in one cohort and validated in a second with significant prognostic impact on MPM patients' survival treated in this protocol (Fig. 3) . 22 Similarly, the Brigham and other groups developed molecular prognostic tests, which, coupled with tumor volume, lymph node status, and histology, also stratify patients in terms of risk of recurrence and death. 23, 24 Pass et al. 25 combined the European Organization for Research and Treatment of Cancer (EORTC) prognostic index and the Cancer and Leukemia Group B index with the plasma biomarkers osteopontin and mesothelin. 26, 27 The reduction in perioperative mortality rates to 3% to 7% in most recent series can be attributed to improved patient selection, technical experience, as well as improved postoperative care. Technical experience has led to decreased operative times and surgical adaptations that include the reconstruction of the diaphragm and pericardium with Gore-Tex (Newark, Delaware) mesh in all patients regardless of side, buttressing of the bronchial stump with well vascularized tissue, and advanced methods of hemostasis including argon beam coagulation and topical hemostatic agents for chest wall bleeding. Along with experience that has led to advances in operative technique, perioperative care has evolved significantly.
The approach to postoperative management begins with a comprehensive intensive care unit team with experience in caring for post-pneumonectomy patients. In a series of 328 consecutive patients undergoing EPP, the most common complication after EPP was reversible atrial fibrillation (44%). 28 Of the complications reported in this series, acute respiratory distress syndrome (ARDS) and pulmonary embolism were most frequently associated with death. To help prevent pulmonary complications, including ARDS, invasive hemodynamic monitoring is used to guide fluid management along with liberal use of bronchoscopy to help clear secretions. For those centers offering induction chemotherapy to their patients, the perioperative anesthesiological protocol is critical as it has been well documented that high intraoperative fraction of inspired oxygen and/or barotrauma can trigger postoperative ARDS. 29 The management can be very challenging in patients following pneumonectomy and -as depicted in Table 1 -it has been shown that the centers' experience plays a crucial role here. Centers with less than five EPPs per year have a significantly higher incidence of postoperative ARDS. 30 Eventually, centers offering extracorporeal life support programs provide to date more experience in handling these patients.
In general, it has been reported from the same STS database, that the center volume influences significantly morbidity and mortality after MPM surgery in univariate analysis (Table 2) .
For monitoring the intrathoracic pressure and to avoid mediastinal shift, a 9-French red rubber catheter can be left in the pneumonectomy space postoperatively. As described by Wolf et al., 31 the catheter can be used to evacuate fluid at increments of 150 mL to stabilize the mediastinum and avoid contralateral lung hyperexpansion and pulmonary edema. 31 Additionally, vocal cord weakness or paralysis may be encountered postoperatively as a result of recurrent laryngeal nerve injury or sacrifice due to involvement with tumor and must be diagnosed and treated promptly to prevent aspiration to the remaining lung.
To identify those at risk for thrombotic events, including pulmonary embolism, all patients at Brigham and Women's institution undergo noninvasive vascular studies to screen for deep vein thrombosis (DVT) preoperatively and on postoperative day 7. Other institutions recommend postoperative therapeutic anticoagulation for several weeks after surgery, but evidence is still lacking. 16 In addition to these complications, bronchopleural fistula (BPF) and empyema can be catastrophic after EPP and pose a unique challenge for the thoracic surgeon. The regular use of perioperative intravenous antibiotics, intraoperative antibiotic lavage of the pneumonectomy space, and buttressing of the bronchial stump with well-vascularized tissues have helped to keep the incidence of BPF and empyema acceptable. 32 For a detailed discussion, Zellos et al. 33 offer a thorough review on the management of these complications. Overall, the frequency of empyema varies considerably in the literature between 3% and 30%. This might be related to the fact that some series do not report late empyema, which is in our experience the most frequent form of empyema, occurring several weeks after discharge. Over the past decades, the accelerated empyema treatment after pneumonectomy with repetitive debridement and subsequent vacuumassisted closure (VAC, KCI Medical GmbH, Ruemlang, Zuerich, Switzerland) (device for negative pressure wound therapy) treatment, where chest was definitively closed within 8 days in 95% (71 of 75) of the patients, has been used. 34 
Pleurectomy/Decortication
The role of P/D in the management of MPM began as an attempt to palliate symptoms caused by the tumor, including dyspnea, cough, and chest pain. 35, 36 This procedure has been performed for a long time in America and in Europe. 37 In comparison to the early experience with EPP, the operative mortality for P/D / (e)P/D has been historically low (<10%), and reduced further in modern series to 0% to 2% as a result of the operation being performed for MCR in patients with early-stage disease. [38] [39] [40] More recently, P/D has become the most common surgical approach because of its perceived lower mortality, improved late pulmonary function, and ability to offer surgery in patients who are older or have limited cardiorespiratory reserve.
The initial portion of the operation is essentially identical to EPP, including extended posterolateral thoracotomy, resection to remove the ipsilateral sixth rib, and extrapleural dissection to remove the tumor and parietal pleura from the chest wall, followed usually by resection of the diaphragm and portion of the pericardium. Alternatively, a broad lateral thoracotomy below the sixth rib can be applied and additional resection of the costal arch can provide a maximal exposure, so that resection of the rib can be avoided (Fig. 4) . Once the entire specimen is only connected by the hilar structures, the parietal pleura is detached (sometimes en bloc), a careful dissection of the entire visceral pleura commences where all visible and palpable tumor down to the fissure is completely removed, and the lymph nodes are dissected. Besides the extension of P/D by performing diaphragmatic or pericardial resection, wedge resection, or even lobectomy, as well as chest wall resection or superior vena cava resection may be performed to achieve complete macroscopic resection. The cavity is irrigated, bleeding is controlled and, on occasion, wedge resections are performed to remove particularly difficult tumors. The lung is then carefully repaired with a stapling device and/or sutures and sealant is applied to minimize air leak post operatively. P/D differs from EPP in that the underlying lung is spared, while complete decortication, or removal of visceral pleura, is performed. The evolution of P/D in the treatment of MPM has come to also include an operation known as (e)P/D which involves P/D as well as the removal of the diaphragm and/or pericardium. This is the operation usually used for curative intent complete macroscopic resection at our institutions, which necessitates diaphragmatic and pericardial reconstruction (Figs. 4-6) .
Despite origins in palliation, P/D / (e)P/D has become the most commonly accepted surgical procedure to achieve MCR and prolong survival, particularly in patients with limited, early-stage disease. 38 The operation is no longer recommended for palliation alone and can be used successfully for the large majority of cases. The MARS 2 trial is currently assessing the role of P/D in a prospective randomized controlled trial and has recruited already 50 patients (status 31.12.2016). As tumor stage advances, the underlying lung parenchyma, fissures, and hilar structures become infiltrated by tumor making MCR by this approach exceedingly difficult, requiring significant dissection and operative time. During the course of P/D / (e)P/D, if MCR is not feasible, some centers consider to achieve MCR by performing EPP as an alternative if the patient is physiologically fit (assessed preoperatively by ventilation-perfusion [V/Q] scan, pulmonary function tests, and transthoracic echocardiography). 41 This is the case when tumor infiltrates lung parenchyma as shown in Figure 7 . Peeling off the visceral pleura from the lung tissue would result in remaining lung tissue being unable to extend and leading to subsequent space problems as shown in Figure 8 .
Mirroring results from EPP series, epithelioid histology and early-stage disease remain significant predictors of survival in patients undergoing P/D / (e)P/D. 38, 42 In mixed cohorts of patients undergoing EPP or P/D / (e)P/ D, epithelial histology, early-stage disease, as well as nodal status continue to predict survival in the setting of multimodality treatment reiterating the importance of preoperative mediastinoscopy and radiographic staging regardless of surgical procedure performed. 38, 43 In a systematic review of P/D / (e)P/D, Cao et al. 44 report overall perioperative morbidity of 13% to 48%. 44 Visceral pleurectomy often involves injury to the underlying lung parenchyma resulting in bleeding and air leak. In some centers, to help prevent these Studies with more than 100 EPPs plus P/Ds completed were included. adj. CTX, adjuvant chemotherapy; ind. CTX, induction chemotherapy; (e)P/D, (extended) pleurectomy/decortication; EPP, extrapleural pneumonectomy; NR, not reported; OS, overall survival; PS0/1/2, performance score; SP, subtotal pleurectomy; TP, total pleurectomy; retro, retrospective.
complications, the patient is maintained on mechanical ventilation with positive end expiratory pressure for the first 24 to 48 hours to keep the lung maximally inflated and help tamponade oozing from the lung. Other centers prefer to minimize positive pressure ventilation to reduce the air leak by extubating the patient immediately in the operating room at the end of the procedure. The most common surgical morbidity associated with P/D / (e)P/D is prolonged air leak and sequelae from prolonged chest tube drainage (3.5% to 57%). 35, 36, [38] [39] [40] 42, 45 Air leak is managed conservatively with maintenance of tube thoracostomy until resolution of the air leak or full expansion of the lung occurs and which may take 2 to 3 weeks. 32 P/D / (e)P/D may also involve significant blood loss (2 to 3 L) despite the advanced hemostatic techniques and should be anticipated by the surgical and anesthesia team and aminocaproic acid is frequently administered prophylactically. 46 Coagulopathy is not uncommon after P/D / (e)P/D or EPP and should be treated aggressively with blood products, recombinant coagulation factors, and occasionally systemic antifibrinolytics in the setting of refractory bleeding. 32 In addition to these complications, P/D / (e)P/D shows a similar morbidity profile to that of EPP, including atrial fibrillation, DVT, myocardial infarction, and empyema.
EPP and P/D -Comparison
The role of surgery itself as part of the multimodality concept has been debated heavily after the release of the Mesothelioma and Radical Surgery (MARS I) trial. 47 The MARS I trial concluded that "EPP within trimodality therapy offers no benefit and possibly harms patients" although only 16 patients of 24 patients assigned to the EPP arm received radical surgery. The study was not designed nor powered to answer the question of benefit or not of EPP, but rather of the feasibility of such a trial. A definitive answer to this question would require an accrual of 670 patients to identify a survival benefit. 48 Also, the criticism of an excessive morbidity and mortality rate is not supported by recently reported trials for trimodality therapy, including EPP, showing that morbidity remains high (22% to 82%) but seems to be manageable in terms of mortality in a range of 2% to 5% in experienced centers. Considering all studies published between 1985 and 2010, a wide range of mortality, from 0% to a maximum of 11.8%, is reported. 49 In contrast, morbidity and mortality rates after (e)P/D are much lower as described in the previous paragraph. 50, 51 Nonetheless, the data on mortality and morbidity remains extremely heterogeneous because of differences in the patient cohorts and different definitions of morbidity. According to the results from a recently published propensity score matched analysis, both procedures appear to have similar rates of major morbidity and with 48% and 58% for EPP and P/D, respectively, in experienced centers, are comparable to published data ranging 10% to 82.6% and 5.9% to 55%, respectively. 40, 52 Each operation bears its specific set of possible and frequent complications that derive from the very characteristics of each operation and both procedures are not directly comparable. After EPP, complications can become life threatening very quickly, such as BPF with subsequent empyema. Empyema can also occur without BPF, which happens usually at later times, weeks after the operation. In contrast, prolonged air leak can occur only after P/D. But this can in return also result in empyema due to ascending infection via the longtime remaining chest drains. Table 3 summarizes the most frequent complications after both procedures.
However, 90-day mortality data have been shown to be a better estimate for the risk of a thoracic operation 53 ; recent data from the United Kingdom show a 13.5% 90-day mortality for EPP and 9.2% for P/D, whereas other centers report 8.0% and 0.0% 90-day mortality for EPP and P/D, respectively. 54 In general, the comparison of EPP, (e)P/D, and P/D is difficult because the available large institutional reports use different inclusion and exclusion criteria as well as different treatment protocols with induction/adjuvant chemotherapy and/or induction/adjuvant chemotherapy as well as different intraoperative treatment. Another problem is the heterogeneous definition of morbidity and major morbidity and the different calculation of overall survival (OS) (from time of diagnosis, chemotherapy start, and surgery). These differences make it difficult to determine which surgical technique is more appropriate to achieve long survival with low morbidity and mortality.
The Systematic Review Unit of the University in Sydney analyzed the surgical treatment of MPM including all relevant data on comparative outcomes of extended P/D and EPP in multimodality settings. In most studies, P/D was usually chosen for earlier stages and EPP for more advanced stages, a decision which is often taken only in the operating theater and not before, due to a lack of reliable clinical staging.
Another important aspect to be considered is the quality of life (QoL) during and after treatment; however, unfortunately, there are not many data available. Rena et al. 65 have included QoL data in their 11 years institutional report comparing EPP and P/D and found a superiority of P/D of EPP in QoL after 6 and 12 months. 65 However, it has been reported for patients undergoing EPP that an improvement in QoL occurred for all parameters at 3 months postoperatively, and another study showing sustained improvement in quality of life after EPP. 69, 70 This holds particularly true for patients with shortness of breath because of entrapped lungs or due to an important V/Q mismatch. Table 4 summarizes the reporting of QoL after EPP.
All studies report QoL below baseline after EPP, some until after 12 months after the operation, or even 19 months, whereas other report return to baseline after 6 months. 47, 65, 73 In a recent analysis of our own cohort of patients undergoing induction chemotherapy in a 2-year period, patients filled out the EORTC QLC-C30 and -C15 and SF-36 self-rating questionnaires preoperatively, 6 weeks, and 4 months after the operation. Some symptoms such as general health score, vitality, social functioning, and mental health were even better 4 months after the operation compared to preoperatively after both procedures (unpublished data).
Regarding long-term oncological outcome, the analysis of the IASLC reported a survival advantage in patients undergoing EPP for early-stage disease with higher survival rates in comparison to patients undergoing P/D. 41 Cao et al. 50 reported that there was insufficient data to perform a meta-analysis in their systematic review comparing EPP with P/D with respect to OS between both procedures. Median OS ranged Figure 10 . Kaplan-Meier curves of overall survival, in all patients and by risk group overall survival in all randomly assigned patients with mesothelioma, per treatment group (A) and in high-risk and low-risk patients, per treatment group (B). The vertical line crosses the x axis at 1 year (primary endpoint). VAT-PP, video-assisted thoracoscopic partial pleurectomy. Reprinted with permission. 91 between 13 and 29 months for extended P/D and 12 to 22 months for EPP. In general, the big ranges of reported survival data are also related to the fact that there are no clear recommendations for follow-up; clearly, for patients included in a more frequent follow-up program, recurrences are documented earlier. There are no validated recommendations regarding the follow-up of patients after surgery, or any other treatment. We recommend follow-up by the surgeon first at 2 and 6 weeks after surgery, then every 4 months for the first 2 years, 6 months until 5 years, then once a year. The British Thoracic Society guidelines recommend patients should be offered 3 to 4 monthly follow-up appointments with an oncologist, respiratory physician, or specialist nurse according to their current treatment plan. 75 Progression-free survival, if reported, is usually longer after EPP in comparison to P/D, and especially the local recurrence rates are higher in P/D groups. 38 The most recent comprehensive meta-analysis was conducted to compare if P/D or EPP is more beneficial to MPM patients. 51 Twenty-four distinct data sets that evaluated long-term outcome of P/D versus EPP were analyzed. One thousand five hundred twelve patients received P/D and 1,391 EPP. The proportion of shortterm mortality (perioperative and 30 days after surgery) was significantly higher in the EPP group (4.5%) versus the P/D group (1.7%). There was no significant difference in 2-year mortality between both groups (23.8% versus 25%) but the included studies showed statistically significant heterogeneity. Among the 17 studies reporting median survival, 53% reported higher median survival with EPP and 47% with P/D. Of the seven studies reporting at least a 2-year survival rate, survival was similar for the two cohorts. The analysis suggests that EPP is associated with a 2.5-fold higher short-term mortality than P/D; therefore, P/D should be preferred if MCR could be achieved ( Fig. 9 and Table 5 ).
Currently a new feasibility study -MARS 2 -is recruiting in the United Kingdom (MARS 2: A Feasibility Study Comparing [Extended] Pleurectomy Decortication Versus no Pleurectomy Decortication in Patients with Malignant Pleural Mesothelioma; ClinicalTrials.gov Identifier: NCT02040272). After 2 cycles of induction chemotherapy with cisplatin/pemetrexed, patients will be randomized to receive chemotherapy only (4 cycles of cisplatin/pemetrexed) or lung-sparing surgery plus chemotherapy (4 cycles of cisplatin/pemetrexed). The primary endpoint of the study is the ability to randomize 50 patients within the first 24 months or the ability to recruit 25 patients within any 6-month period.
Palliative Surgery
Parenchyma-sparing debulking P/D or partial pleurectomy should be considered in symptomatic patients who decline or are not eligible for MCR due to stage or status, and have not responded to thoracentesis or catheter drainage, as freeing an entrapped lung may Figure 11 . Location of isolated ipsilateral chest wall recurrence of malignant pleural mesothelioma after cytoreductive surgery. Reprinted with permission. improve respiratory function. 84 This palliative surgical approach can also be performed by video-assisted thoracic surgery (VATS) with the intention to improve the QoL of these patients. [85] [86] [87] [88] Alternatively, indwelling pleural catheters, which can be placed in an outpatient setting and are easy to handle, are a very good alternative for a rapid palliation of recurring pleural effusions. 89, 90 Talc pleurodesis is efficient in prevention of pleural effusion recurrence but requires a full expansion of the lung.
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Recently the MesoVATS trial has randomized MPM patients to undergo VATS pleurectomy versus talc pleurodesis via an indwelling intercostal chest drain or via thoracoscopy. Survival rates were about the same but VATS pleurectomy significantly improved control of recurrent build-up of fluid in the lungs in the first 6 months after the procedure and improved quality of life for 12 months (Fig. 10) . 91 
Surgery for Recurrence -Chest Wall Resection
Locally recurrent disease is a common problem in patients who undergo surgery for MPM. It usually occurs in the ipsilateral thoracic cavity or chest wall and can occasionally spread to the retroperitoneum and abdominal cavity. In most cases, this type of recurrence is handled by localized radiation therapy and chemotherapy. However, there are special circumstances where the recurrence is limited and potentially resectable.
The literature reporting the outcome of surgical second line treatments of MPM recurrence is scarce. The only available paper reporting specifically about the outcome of patients after chest wall resection (CWR) is Burt et al. 92 In this paper, 47 patients initially treated with EPP (n 3 2) or P/D (n ¼ 15) were analyzed. Median time to relapse after radical surgery was 16.1 months. After CWR, 63% of the patients had direct closure of the defect, 28% required mesh construction, and 9% underwent a muscle flap closure. No morbidity or 30-day mortality occurred and the median hospital stay was 3 days (range, 0 to 12 days). The median survival after CWR was 20.4 months in patients with epithelioid histologic subtype (n ¼ 32) and 7.4 months in patients with biphasic histologic subtype (n ¼ 15) at initial EPP or P/D.
Other papers report surgical treatment of relapse in general and include not only CWR, but also contralateral pleurectomy, resection of a mediastinal tumor, radical retroperitoneal resection, pectoral muscle resection, and upper lobe segmentectomy. [93] [94] [95] In addition, the number of patients receiving second-line surgery was low and ranged from 2 to 16. [93] [94] [95] For selected patients, curative CWR is an effective strategy with minimal morbidity and promising survival rates. Patients with prolonged time to relapse seem to benefit most. CWR can be applied in conjunction with other adjuvant modalities for the treatment of localized ipsilateral relapse. In particular, upcoming radiological strategies, such as stereotactic body radiation therapy for localized chest wall recurrences might be a good noninvasive alternative for this patient group (Fig. 11 and Table 6 ).
Conclusion
Surgery has an important role in the interdisciplinary management of MPM at all stages; therefore, surgeons should be involved in the multimodality care of these patients. The surgical treatment continues to evolve in parallel with the medical treatment of this malignancy. In the past decade, there has been a movement to focus on P/D as the definitive treatment for this disease.
